Combination paclitaxel (TaxolR)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer
- 1 May 1997
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 7 (s1) , 9-13
- https://doi.org/10.1046/j.1525-1438.7.s1.5.x
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1995
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of Clinical Oncology, 1994